PT-141

PT-141 (Bremelanotide) is a centrally acting melanocortin receptor agonist used to enhance sexual desire and arousal in both men and women. Originally developed to treat sexual dysfunction, it is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women and is also commonly used off-label in men with low libido or erectile dysfunction—especially when psychological or central causes are suspected. Unlike traditional ED medications, PT-141 works through the brain rather than blood flow.

PT-141 stimulates the brain’s arousal centers through the melanocortin system:

1. CNS-Based Arousal Enhancement
   • PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, increasing sexual desire and drive by acting on the central nervous system.
2. Independent of Blood Flow
   • Unlike PDE5 inhibitors (like sildenafil or tadalafil), PT-141 does not depend on nitric oxide pathways or vascular mechanisms—making it effective for both genders and for arousal-related dysfunction.
3. Rapid, On-Demand Effect
   • Administered via subcutaneous injection 45–60 minutes before sexual activity, PT-141 enhances arousal, responsiveness, and sensitivity for several hours.

• Inject 1 hour before sexual activity (typically 1.75mg dose)
• Onset: 45–60 minutes, duration: 6–12 hours
• Do not exceed 1 dose in 24 hours or 8 doses per month (per FDA guidelines for women)
• Results improve with repeated, consistent use over time
• Safe to combine with TRT, HRT, or PDE5s (under supervision)
• Missed dose? PT-141 is on-demand—only use when needed

Common Side Effects:
• Nausea (transient)
• Flushing or warmth
• Headache
• Injection site reactions

Less Common / Monitor If Present:
• Elevated blood pressure (temporary)
• Fatigue or yawning
• Dizziness
• Darkening of gums or skin (rare with prolonged use)